Imextor SR 1000 Tablet contains Imeglimin 1000 mg, an oral antihyperglycemic agent indicated for the management of type 2 diabetes mellitus. Imeglimin is a novel tetrahydrotriazine compound that improves glycemic control through a dual mechanism of action by enhancing insulin sensitivity and promoting insulin secretion. It acts on mitochondrial bioenergetics to reduce hepatic glucose production and increase peripheral glucose uptake, thereby addressing both insulin resistance and beta-cell dysfunction. Imextor SR 1000 is formulated as a sustained-release tablet to provide a consistent plasma concentration, allowing once or twice-daily dosing for improved patient compliance. Clinical studies have demonstrated its efficacy in lowering fasting plasma glucose and HbA1c levels, either as monotherapy or in combination with other antidiabetic agents. The safety profile of Imeglimin is generally favorable, with the most common adverse effects being mild gastrointestinal disturbances. It is contraindicated in patients with severe renal impairment and should be used cautiously in those with hepatic dysfunction. Regular monitoring of blood glucose and renal function is recommended during therapy. Imextor SR 1000 offers a promising therapeutic option for patients requiring improved glycemic control in type 2 diabetes management.